Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients

Jingyu Liu1,2, Jing Li1,2, Hui Wang1,3, Yikai Wang4, Qiongzhi He5, Xuefeng Xia5, Zhe-Yu Hu1,2* and Quchang Ouyang1,2*

Abstract

Background: Among breast cancer (BC) patients, near 40% are post-menopause, and 70%–80% are hormone receptor (HR)-positive. About 30%–40% BC patients who are diagnosed as invasive carcinoma HR-positive BC would eventually develop metastatic breast cancers. In 2016, FALCON trial proves Fulvestrant as an effective first-line endocrine therapy for post-menopause HR-positive advanced BC (ABC) patients. But even after FALCON published, Fulvestrant is rarely used as first-line in real world ABC patients in China.

Method: In this study, 136 Fulvestrant users were enrolled from 2015. To investigate the clinical and genetic risk factors for Fulvestrant treatment response in real world data, biostatistic and bioinformatic analysis tools were adopted.

Result: KM curves showed that Fulvestrant first-line users had a median progression-free survival (mPFS) of 15.67 months, which was longer than the second-line users and third (or higher)-line users (mPFS = 7.47 and 5.43 months, respectively). 16 s (or higher)-line users were voluntarily received circulating tumor DNA (ctDNA) testing after progression. ctDNA testing results showed that compared to patients with PFS longer than 6 months, Fulvestrant users with PFS less than 6 months had a significantly higher mutation rate of ESR1 or ERBB2 gene (0/6 vs 6/10, Fisher's Exact p-value = 0.03). Multivariate COX regression analysis showed that clinical features, including lymph node metastasis and HER-2 positive, were significant risk factors for poor PFS [hazard ratio (HR) = 2.396 and 2.863, respectively]; high portion of estrogen receptor-positive cells was significant protective factor (HR = 0.663). Propensity-score matching (PMS) analysis suggested that visceral metastasis, prior palliative chemotherapy, and old age at Fulvestrant usage were not significant influential factor for PFS.

Conclusion: First-line Fulvestrant usage could guarantee a better prognosis than higher-line usage. ESR1 or ERBB2 mutation was found to be related to poor PFS in higher-line Fulvestrant users.

Keywords: Post-menopause HR-positive advanced breast cancer, Fulvestrant, First-line, ctDNA ERBB2 and ESR1 mutation, Poor progress-free survival (PFS)
Background
Breast cancer is the leading mortality cause for females worldwide [1]. The incidence rate of breast cancer increased significantly from 2000, and has become the most common malignant disease for females. Among breast cancer patients, near 40% are post-menopause, and 70%–80% are hormone receptor (HR)-positive. In women who present with early stage hormone receptor-positive breast cancer, metastatic disease eventually develops in up to 40%, although relapses may occur late, up to three decades after the initial diagnosis [2]. The goals of treatment for advanced breast cancer (ABC) patients include symptoms alleviation, quality of life (QOL) improvement, and survival extension [3]. To achieve this goal, endocrine therapy is an efficient treatment strategy to target estrogen receptor (ER), to block ER’s interaction with estrogen and to inhibit ER downstream pathways. Endocrine therapy is the first-line treatment regimen for ER-positive ABC patients [4], except for severe visceral conditions which need rapid control for the disease.

Fulvestrant, a selective ER degrader (SERD), is able to bind to ER, down-regulate ER protein and block ER function [5]. Based on an open-accessed, random and multi-center phase III clinical trial No. 0021, Fulvestrant has the similar efficiency with Anastrozole in post-menopause ER-positive ABC patients who fail in the first-line endocrine therapy; the median time-to-progression (TTP) is 5.4 months and 5.1 months in Fulvestrant group and Anastrozole group, respectively [hazard ratio (HR) = 0.98, 95% confidence interval (CI) = 0.8–1.21, p = 0.84] [5]. Both in vivo and in vitro studies prove that Fulvestrant inhibits ER transcription and promotes ER degradation in a dose-dependent manner [6–9]. Clinical research further confirms that Fulvestrant 500 mg is significantly superior to 250 mg [HR (95% CI) = 0.8 (0.68, 0.94), p = 0.006]; the median overall survival (OS) for Fulvestrant 500 mg group is 25.1 months, while the median OS for Fulvestrant 250 mg group is 22.8 months [10]. Thus, American Society of Clinical Oncology (ASCO) recommends Fulvestrant 500 mg to be the standard treatment for post-menopause ER-positive ABC patients who fails in the first-line endocrine therapy.

According to FALCON trial (a phase III clinical trial), Fulvestrant 500 mg is approved to be the first-line endocrine therapy for post-menopause ER-positive ABC patients. Fulvestrant 500 mg can significantly improve the PFS, compared with Anastrozole group [HR (95% CI) = 0.797 (0.637, 0.999), p = 0.0486]; the median PFS for Fulvestrant 500 mg group is 16.6 months, while the median PFS for Anastrozole group is 13.8 months [11]. But for visceral metastatic patients, the median PFS of Fulvestrant and Anastrozole users are 13.5 months and 15.9 months, respectively; in non-visceral metastatic group, the median PFS for Fulvestrant users is 22.3 months (HR = 0.59, non-visceral metastatic subgroup vs visceral metastatic subgroup) [11]. This finding implies a poorer prognosis for visceral metastatic Fulvestrant users. Based on a multi-center retrospective analysis among ABC Fulvestrant users, patients with first-line usage, no prior palliative chemotherapy, and lower histology/nuclear grade have better prognosis; visceral metastasis have no significant effect on prognosis [12]. Some other opinions are obtained from Graham research findings; they support that patients with visceral metastasis benefit more from Fulvestrant treatment [13, 14].

In real world practice, except HR status and tumor burden, the drug sensitivity and anti-cancer efficiency are always the priority issues in clinical treatment decision [3]. Although Fulvestrant is a promising and well-tolerant anti-breast cancer drug, it still has drug-resistant problem like other endocrine drug [15]. Recent researches suggest that PIK3CA mutation, ESR1 mutation, and ER/HER2 crosstalk are the underlying molecular mechanisms for Fulvestrant resistance [15–19]. Patients with these resistant-related events always have poor prognosis. Therefore, molecular evaluation before treatment would provide oncologists the clues for future drug sensitivity and prognosis. Circulating tumor DNA (ctDNA) testing is highly efficient in detecting ESR1, PI3K and TP53 mutations in metastatic BC patients [20–22]. Due to the spatial heterogeneity of breast metastases, ctDNA testing is even more useful than tumor tissue genetic testing.

In this study, we aimed to collect real world data to retrospectively analyze the potential risk factors for Fulvestrant treatment where risk candidates included both clinical factors and genetic mutations.

Materials and methods
Patient cohort and clinical data collection
136 BC patients with relapse or metastases who received Fulvestrant treatment were enrolled in this study. These patients received treatment at the Department of Breast Cancer Medical Oncology in Hunan Cancer Hospital from June 2015 to August 2018. The study was approved by the Ethics Committee at the Hunan Cancer Hospital. Informed consent was obtained from each patient prior to study onset. Specially, inclusion criteria includes: (1) cytologically or histologically confirmed AJCC stage IIIB–IV breast cancer patients, including locally unresectable ABC, relapsed and metastatic BC; (2) post-menopause patients; (3) based on ASCO definition, ER is positive and/or PR is positive; (4) according to RECIST 1.1 standard [23], patients had at least one detectable target lesion; (5) Performance score (PS) was 1–2 points.
Excluding criterion were (1) multiple primary cancer patients; (2) premenopausal females; (3) Fulvestrant was administrated combined with other endocrine therapy, chemotherapy or targeting therapy.

Basic demographic and clinical information were collected, including age of primary BC diagnosis, age at Fulvestrant treatment, disease free survival (DFS), HR/human epidermal growth factor receptor 2 (HER2) status, TNM stage at primary BC diagnosis, treatment history at diagnosis (including primary BC surgery/radiation, chemotherapy, and endocrine therapy history), palliative treatment history after relapse or metastasis, and metastatic sites.

**Definition of progression and time-to-progression**

The RECIST has established the guidelines for measurement of the tumoral targets and to assess the response to treatments. According to RECIST 1.1 standards, progression is defined as 20% increase in tumoral targets' volume. In targeted therapy-based treatment trials of metastatic BC patients, PFS highly correlates with overall survival [24, 25]. Therefore, PFS was applied to evaluate the patient's responses to Fulvestrant in this study.

Time to Treatment Failure (TTF) was the second measurement in this study. According to previous publication [12], TTF was defined as the period of time between the start and the termination of Fulvestrant treatment. If a patient was considered as disease progressed (PD), then the termination day was the day of progression; if a patient received palliative or replaced treatment, then the termination day was 28 days later to the last day of Fulvestrant treatment; if a patient requested to stop Fulvestrant and change to use other drugs, the termination day was 28 days later after last Fulvestrant treatment day or the start day of the next regimen, depending on which day was earlier; if a patient had PD, but the progression day could not be identified, then the termination day was the last Fulvestrant treatment day plus 28 days, or the start day of next regimen, depending on which day was earlier.

**Circulating tumor DNA testing**

To investigate the genetic risk factors associated with Fulvestrant resistance and poor prognosis, ctDNA test was performed in 16 volunteers among enrolled 136 Fulvestrant users. The peripheral blood samples were collected and DNA extraction procedure followed the protocol as described previously [20]. Genomic DNA (gDNA) was sequenced as the normal control sample. Capture probes were designed to cover coding sequences and hot exons of 1021 genes that were frequently mutated in solid tumors. A detailed description of the capture experiments has been reported [20]. Single nucleotide variants (SNV) were called using MuTect (version 1.1.4) and NChot softwares [20]. Small insertions and deletions (Indels) were called using GATK. Somatic copy number alterations were identified with CONTRA (v2.0.8). Significant copy number variation was expressed as the ratio of adjusted depth between ctDNA and control gDNA. The final candidate variants were all manually verified in the Integrative Genomics Viewer.

**Propensity score match**

A 1:1 propensity score matching (PSM) analysis was performed to reduce the potential bias between the two subgroups. To evaluate the effect of potential factors on Fulvestrant treatment without bias, propensity scores were calculated through logistic regression for each patient in compared subgroups. The covariates included in the logistic regression were all other clinical candidates except the PSM-evaluated one. Patients in each of the two groups were matched based on the propensity score. Covariate balance between each of the two groups was examined by Chi square test. Survival comparisons were then performed for the matched patients using the same methods as those in the unmatched patients.

**Statistical analyses**

Numerical variables were summarized as the mean (standard deviation) and median (interquartile range). Categorical variables were reported as counts (percentage). An analysis of variance was used to compare continuous variables with symmetrical distributions across subgroups. Chi square tests and Fisher’s exact tests (n < 5) were used to compare categorical variables between subgroups. Mantel–Haenszel Chi square tests were used, when group number was more than two. Cox regression analysis was used to evaluate the univariate and multivariate risk of candidate risk factors for progression. Kaplan–Meier (KM) curves were used to plot survival distributions against progression, and the log-rank test was used to assess differences in PFS among subgroups. Receiver operating characteristic (ROC) curve was then calculated to determine the optimal cutoff of the age at Fulvestrant usage that maximized sensitivity and specificity in predicting a better PFS. All tests of hypotheses were two-tailed and conducted at a significance level of 0.05, and at a marginal significance level of 0.15. Statistical analyses were conducted using SAS 9.4.

**Results**

**Demographic and clinical features**

136 Fulvestrant users were enrolled in this study. 17 (12.5%) patients received Fulvestrant as the first-line endocrine treatment. 61 (44.85%) patients received Fulvestrant as the second-line endocrine treatment.
58 (42.65%) patients received Fulvestrant as the third or even later lines of endocrine treatment. Patients with Fulvestrant at later (≥ third) line were younger at diagnosis and Fulvestrant usage, and had shorter DFS (Table 1). Moreover, more late users had surgery menopause, visceral metastasis, and palliative chemotherapy (Table 1). Other clinical features, such as HR/HER2 status, nuclear or histological grade, stage, menopause method, primary treatment history, bone and lymph node metastasis were not significantly distinct among Fulvestrant early users and late users.

### Table 1 Clinical characteristics of ER-positive patients with Fulvestrant usage (n = 136)

| Covariates                     | Level         | All patients (n = 136) | Fulvestrant usage | p-value† |
|--------------------------------|---------------|------------------------|-------------------|----------|
|                                |               | First line (n = 17)    | Second line (n = 61) | ≥ Third line (n = 58) |
| Age at diagnosis (years)       |               | 46.67 ± 9.66, 46 (39, 55) | 48.26 ± 8.62, 48.5 (39.5, 56) | 48.19 ± 10.04, 47 (39, 58) | 44.69 ± 9.07, 44 (39, 50) | 0.07 |
| Age at FX usage (years)        |               | 53.37 ± 9.52, 53 (47, 62) | 56.63 ± 7.16, 55.5 (52.5, 63) | 56.43 ± 9.74, 55.5 (47, 62) | 51.19 ± 9.27, 51 (45, 64) | 0.01 |
| Weight                         |               | 58.67 ± 12.37, 58 (54, 62) | 56.33 ± 2.88, 56.5 (55, 58) | 57.21 ± 7.73, 57 (53, 61) | 60.10 ± 15.94, 58 (54, 62) | 0.27 |
| ER Negative                    |               | 2 (1.47%) | 3 (2.32%). | 1 (1.64%) | 2 (3.45%) | 0.90 |
| PR Positive                    |               | 118 (86.76%) | 14 (82.35%) | 55 (90.16%) | 49 (84.48%) | 0.52 |
| HER2 Positive                  |               | 13 (9.56%) | 3 (17.65%) | 3 (4.92%) | 7 (12.07%) | 0.17 |
| Nuclear or histological grade  | 2             | 35 (25.74%) | 3 (17.65%) | 18 (29.51%) | 14 (24.14%) | 0.84 |
| Stage I                        |               | 15 (11.03%) | 1 (5.88%) | 5 (8.20%) | 9 (15.52%) | 0.35 |
| Stage II                       |               | 35 (25.74%) | 5 (29.41%) | 17 (27.87%) | 13 (22.41%) | 0.49 |
| Stage III                      |               | 53 (38.97%) | 4 (7.55%) | 26 (42.62%) | 23 (39.66%) | 0.90 |
| Menopause Natural menopause    |               | 83 (61.03%) | 13 (76.47%) | 41 (67.12%) | 29 (50.00%) | 0.02 |
| Menopause OFS (OF + surgery)   |               | 24 (17.65%) | 4 (23.53%) | 10 (16.39%) | 10 (17.24%) | 0.78 |
| Treatment of primary diagnosis | Primary site surgery | 134 (98.53%) | 17 (100%) | 60 (98.36%) | 57 (98.28%) | 0.49 |
|                                | Primary site radiation | 52 (38.24%) | 5 (29.41%) | 23 (37.70%) | 24 (41.38%) | 0.67 |
|                                | Chemotherapy   | 117 (86.03%) | 14 (82.35%) | 52 (85.25%) | 51 (87.93%) | 0.78 |
|                                | Endocrine therapy | 100 (73.53%) | 13 (76.47%) | 40 (65.57%) | 47 (81.03%) | 0.15 |
| Treatment after relapse or metastasis | Radiation | 21 (15.44%) | 0 (0%) | 10 (16.39%) | 11 (18.97%) | 0.15 |
|                                | Chemotherapy   | 80 (58.82%) | 6 (35.29%) | 28 (45.90%) | 46 (79.31%) | <0.0001 |
| DFS (years)*                   |               | 4.86 ± 3.38, 4.24 (2.48, 6.96) | 8.28 ± 3.94, 7.93 (5.89, 10.64) | 5.01 ± 3.21, 4.69 (2.84, 7.36) | 3.61 ± 2.57, 3.07 (2.00, 5.10) | <0.0001 |
| Metastatic sites               | Lymph nodes   | 53 (38.97%) | 10 (58.82%) | 24 (39.34%) | 19 (32.76%) | 0.17 |
|                                | Bone          | 93 (68.38%) | 8 (47.06%) | 45 (73.77%) | 40 (68.97%) | 0.12 |
|                                | Visceral      | 68 (50.00%) | 6 (35.29%) | 30 (49.18%) | 32 (51.17%) | 0.01 |

* DFS indicated the time from diagnosis of BC to the diagnosis time of relapse or metastasis. For † p-value calculation, ANOVO analysis was used to compare continuous variables with symmetrical distributions across subgroups, Mentel–Haenszel Chi square tests and Fisher’s exact tests (n < 5) were used to compare categorical variables between subgroups.
Clinical risk factors for poor treatment response
To evaluate the risk factors for poor response in Fulvestrant users, univariate COX regression analyses were performed. As shown in Table 2, compared to the first-line usage, the second-line treatment was a marginal risk factor for disease progression (HR [95% CI] = 1.911 [0.803, 4.547], p = 0.14) and treatment failure (TTF) (HR [95% CI] = 2.008 [0.849, 4.745], p = 0.11); compared to the first-line usage, the late Fulvestrant usage (≥ third line) was a significant risk factor for both disease progression (HR [95% CI] = 2.420 [1.026, 5.711], p = 0.04) and treatment failure (HR [95% CI] = 2.668 [1.135, 6.272], p = 0.03). Other significant risk factors included HER2-positive status, higher nuclear/histological grade, advanced BC stage at diagnosis, and lymph node metastasis at cancer relapse or metastasis.

To avoid confounding effects, multivariate COX regression analysis was performed. As shown in Additional file 1: Table S1, compared to the first-line usage, both the second-line and ≥ third-line usages were risky

Table 2 Univariate COX regression analysis for the risk factors for progression (PFS) and time-to-failure (TTF) in Fulvestrant users

| Covariates                        | Level                  | PFS Hazard ratio (95% CI) | p-value | TTF Hazard ratio (95% CI) | p-value |
|-----------------------------------|------------------------|--------------------------|---------|--------------------------|---------|
| Fulvestrant usage                 | First line             | Ref                      | Ref     | Ref                      | Ref     |
|                                   | Second line            | 1.911 (0.803, 4.547)     | 0.14    | 2.008 (0.849, 4.745)     | 0.11    |
|                                   | ≥ Third line           | 2.420 (1.026, 5.711)     | 0.04    | 2.668 (1.135, 6.272)     | 0.03    |
| Age at diagnosis (years)          |                        |                          |         |                          |         |
|                                   | < 62                   | 1.001 (0.977, 1.026)     | 0.94    | 1.004 (0.981, 1.028)     | 0.72    |
|                                   | ≥ 62                   | 0.990 (0.966, 1.015)     | 0.44    | 0.994 (0.971, 1.017)     | 0.60    |
| Age at FX usage (years)           |                        |                          |         |                          |         |
|                                   | < 62                   | Ref                      | Ref     | Ref                      | Ref     |
|                                   | ≥ 62                   | 0.753 (0.441, 1.288)     | 0.30    | 0.714 (0.425, 1.199)     | 0.20    |
| Weight                            |                        |                          |         |                          |         |
|                                   | Ref                    | 0.999 (0.982, 1.016)     | 0.37    | 0.997 (0.979, 1.015)     | 0.75    |
|                                   | ≥ 62                   | 0.950 (0.886, 1.019)     | 0.15    | 0.948 (0.887, 1.013)     | 0.11    |
| DFS (years)                       |                        |                          |         |                          |         |
|                                   | Ref                    | 0.610 (0.128, 2.903)     | 0.53    | 0.795 (0.168, 3.763)     | 0.77    |
|                                   | ≥ 62                   | 0.693 (0.318, 1.510)     | 0.36    | 0.869 (0.404, 1.869)     | 0.72    |
|                                   | Ref                    | 0.706 (0.326, 1.528)     | 0.71    | 0.894 (0.417, 1.916)     | 0.77    |
| ER                                | Negative               | Ref                      | Ref     | Ref                      | Ref     |
|                                   | ≥ 62                   | 0.610 (0.128, 2.903)     | 0.53    | 0.795 (0.168, 3.763)     | 0.77    |
|                                   | 1%–50%                 | 0.693 (0.318, 1.510)     | 0.36    | 0.869 (0.404, 1.869)     | 0.72    |
|                                   | 50%–100%               | 0.706 (0.326, 1.528)     | 0.71    | 0.894 (0.417, 1.916)     | 0.77    |
|                                   | Unknown                | 0.610 (0.128, 2.903)     | 0.53    | 0.795 (0.168, 3.763)     | 0.77    |
| PR                                | Positive               | 1.171 (0.602, 2.277)     | 0.64    | 1.073 (0.582, 1.981)     | 0.82    |
|                                   | Ref                    | 2.024 (0.997, 4.109)     | 0.05    | 1.833 (0.936, 3.587)     | 0.08    |
| HER2                              | Negative               | Ref                      | Ref     | Ref                      | Ref     |
|                                   | Positive               | 1.171 (0.602, 2.277)     | 0.64    | 1.073 (0.582, 1.981)     | 0.82    |
|                                   | Ref                    | 2.024 (0.997, 4.109)     | 0.05    | 1.833 (0.936, 3.587)     | 0.08    |
| Nuclear or histological grade     | 2                      | Ref                      | Ref     | Ref                      | Ref     |
|                                   | 3                      | 1.683 (0.942, 3.004)     | 0.08    | 1.476 (0.861, 2.530)     | 0.15    |
|                                   | Unknown                | 1.410 (0.782, 2.541)     | 0.25    | 1.219 (0.694, 2.139)     | 0.49    |
| Stage at BC diagnosis             | 0/I                    | Ref                      | Ref     | Ref                      | Ref     |
|                                   | II                     | 1.476 (0.791, 2.755)     | 0.22    | 1.378 (0.759, 2.503)     | 0.29    |
|                                   | II/IV                  | 1.709 (1.001, 2.919)     | 0.05    | 1.607 (0.965, 2.666)     | 0.07    |
| Menopause                         | Natural menopause      | Ref                      | Ref     | Ref                      | Ref     |
|                                   | OFS (OFS + surgery)    | 0.850 (0.463, 1.560)     | 0.60    | 0.697 (0.384, 1.265)     | 0.24    |
|                                   | Surgery                | 1.145 (0.673, 1.948)     | 0.62    | 1.049 (0.624, 1.764)     | 0.86    |
| Treatment of primary diagnosis    | Primary site surgery   | 0.807 (0.112, 5.837)     | 0.83    | 0.515 (0.126, 2.107)     | 0.36    |
|                                   | Primary site Radiation | 1.075 (0.688, 1.682)     | 0.75    | 1.133 (0.738, 1.740)     | 0.57    |
|                                   | Chemotherapy           | 0.995 (0.495, 2.003)     | 1.00    | 0.968 (0.499, 1.881)     | 0.92    |
|                                   | Endocrine therapy      | 1.223 (0.729, 2.049)     | 0.45    | 1.263 (0.771, 2.068)     | 0.33    |
| Treatment after relapse or metastasis | Radiation (Yes vs No) | 1.091 (0.589, 2.022)     | 0.78    | 0.879 (0.476, 1.621)     | 0.68    |
|                                   | Chemotherapy (Yes vs No)| 1.394 (0.873, 2.226)    | 0.16    | 1.413 (0.905, 2.206)     | 0.13    |
| Metastatic sites                  | Lymph nodes            | 1.623 (1.041, 2.531)     | 0.03    | 1.509 (0.986, 2.311)     | 0.06    |
|                                   | Bone                   | 1.096 (0.682, 1.762)     | 0.83    | 1.180 (0.745, 1.869)     | 0.57    |
|                                   | Visceral               | 1.036 (0.671, 1.601)     | 0.87    | 0.967 (0.637, 1.468)     | 0.87    |
for progression and treatment failure in multivariate COX model. HER2-positive was risk for progression (HR = 2.396, p = 0.04), while 50%–100% ER-positive was protective for progression (HR = 0.663, p = 0.02). In multivariate COX model, advanced stage at diagnosis and lymph node metastases were also significant risk factors for progression and treatment failure. Interestingly, older age at Fulvestrant usage was a significant protective factor in multivariate COX model (HR = 0.88, p = 0.03, Additional file 1: Table S1).

Survival analysis for patients stratified by significant candidates

To further evaluate the effect of above significant factors on Fulvestrant users, lifetest and PSM analyses were conducted. As shown in Fig. 1, the median PFS for all enrolled patients was only 6.53 months. But, patients with Fulvestrant first-line treatment had longer mPFS (15.67 months), which was much longer than Fulvestrant second-line users (mPFS = 7.47 months) and patients with Fulvestrant line ≥ 3 treatment (mPFS = 5.43 months). Lifetest showed a significant better PFS for first-line users than second (or above)-line users (p-value = 0.0635, Fig. 2a left). In PSM data (right panel of Fig. 2a), p-value was not significant due to small sample size (a total of 30 samples after PS matched), but the Kaplan-Merier (KM) curve of first-line Fulvestrant users (blue line) was distinctively higher than the KM curve of higher line users (red line).

Lymph node metastasis was a significant risk factor for poor PFS in both univariate and multivariate COX model; PSM analysis further confirmed this effect (Fig. 2b, p = 0.07 in PSM data). However, visceral metastasis did not show a significant risk effect on PFS for Fulvestrant users in both raw data and PSM data (Fig. 2c). As for prior palliative chemotherapy before Fulvestrant treatment, it showed a marginal risk effect for PFS in KM curve analysis (Fig. 2d left panel, logrank p = 0.11) and univariate COX analysis (p = 0.16, Table 2); but in PSM data, the stratified KM curves were most the same (Fig. 2d right panel, logrank p = 0.96). Also, because patients with prior palliative chemotherapy were all second-line or higher-line Fulvestrant users (Table 1), prior palliative chemotherapy showed a marginal risk effect on PFS (Table 2); when PSM removed the unbalanced distribution of patients with prior palliative chemotherapy among distinct lines of Fulvestrant users, the risk effect of prior palliative chemotherapy disappeared (Fig. 2e).

cDNA mutations related to Fulvestrant resistance and poor prognosis

To explore the molecular basis of Fulvestrant resistance, 16 Fulvestrant second- or higher-line users participated ctDNA testing. According to their PFS lengths, these patients were divided into two subgroups: PFS < 6 months and PFS > 6 months. Figure 3 ranked the mutated genes. If 1 patient had two mutations within in one gene (e.g., patient ID = 8 had two PIK3CA mutations, p.E545K and p.E726K, Fig. 4a), this gene would be counted twice in Fig. 3. As shown in Fig. 3, in patients with poor prognosis (PFS < 6 months), TP53, ERBB2 and ESR1 gene mutations were the top frequent mutations; other genes, including ARD1A, FBXW7, DDR2, ect, were also frequent mutations.
For patients with PFS longer than 6 months, no ERBB2 and ESR1 gene mutations were detected.

To explore the correlation of TP53, PIK3CA, ERBB2 and ESR1 mutations with poor PFS, fisher’s exact test was used to compare the patients’ gene mutation frequencies between two PFS subgroups. Here, if 1 patient had mutations in one gene, no matter how many mutations were there in 1 patient, only 1 patient is counted for frequency comparison. As shown in Table 3, when compared to PFS > 6 months subgroup, PFS < 6 months subgroup had significantly higher mutation frequency of ESR1 or ERBB2 mutation (p = 0.03). In addition, marginally more patients with PFS < 6 months had TP53, ESR1 or ERBB2 mutations (p = 0.011).

Fulvestrant resistance were related to ESR1 mutation or ERBB2 mutation

Among 16 Fulvestrant users with ctDNA testing, five received the second-line Fulvestrant treatment, and 11 patients received ≥ third-line Fulvestrant treatment (Additional file 2: Figure S1). In second-line Fulvestrant users, PFS of 2/5 (40%) patients were less than 6 months (ID = 9 and ID = 11), while PFS of the rest 3/5 (60%) patients were longer than 6 months (ID = 4, 5, 8, Fig. 4a). In ≥ third-line Fulvestrant users, PFS of 8/11 (73%) patients were less than 6 months, and PFS of 3/11 (27%) patients were longer than 6 months (ID = 7, 10, 13, Fig. 4b). In all 10 PFS < 6 months patients, two had ESR1 missense mutation (ID = 11 p.AS58T and ID = 12 p.D538G), 4 patients had ERBB2 mutation (ID = 6 p.Y772_A775dup; ID = 9 p.S310F; ID = 14 p.G776delins; ID = 15 had both ERBB2 amplification and ERBB2 p.E844K missense mutation Fig. 4b), and 3 patients had TP53 mutation (ID = 9, 11 and 17). In all 6 PFS > 6 months patients, none of them had ESR1 or ERBB2 mutations.

Discussion

In this study, we retrospectively analyzed the clinical factors that might influence the treatment response of advanced ER-positive breast cancer patients to Fulvestrant. We also utilized ctDNA testing to investigate Fulvestrant-related drug resistant mutations. By using COX regression analysis, we found that Fulvestrant first-line treatment, older age at Fulvestrant usage, and high ER-positive percentage were protective factors for PFS in Fulvestrant users. But, ≥ second-line Fulvestrant usage, HER2-positive, higher nuclear or histological grade, late stage (stage III/IV) at BC diagnosis, and lymph node metastases were important risk factors for poor PFS prognosis for Fulvestrant users (Table 2 and Additional file 1: Table S1). PSM analysis further confirmed the risk effect of late-lines treatment and lymph node metastasis (Fig. 2).

Currently, Fulvestrant is recommended as the standard first-line endocrine therapy for post-menopause ER-positive advanced BC patients. But, based on our study, only 17/136 (12.5%) post-menopause ER-positive ABC patients received first-line Fulvestrant treatment, 61/136 (44.85%) patients received second-line Fulvestrant treatment, and 58/136 (42.65%) patients received third-line (and higher lines) Fulvestrant treatment. The median PFS for first-line, second-line and third-line (including higher lines) users were estimated to be 15.67 months, 7.47 months and 5.43 months, respectively (Fig. 1). Therefore, the earlier Fulvestrant is used, the better prognosis patients would have. In addition, compared to the ER status at diagnosis or surgery biopsy, ER status would change as disease progression in later stage. Drug resistance would also appear after multi-line endocrine therapies. Therefore, based on the findings of this study, we recommended ER-positive ABC patients to receive Fulvestrant treatment as early as possible. Multivariate COX regression analysis suggested high ER-positive percentage (50–100%) to be a beneficial factor for prognosis (Additional file 1: Table S1). This was consistent with clinical observations that patients with high ER level were more sensitive to endocrine therapy and thus the prognosis would be better.

Univariate COX analysis showed prior palliative chemotherapy as a marginal risk factor for poor prognosis. The median PFS for Fulvestrant users who had no prior palliative chemotherapy was 8.47 months, compared to patients with prior palliative chemotherapy with median PFS of 5.8 months (logrank p-value = 0.1174, Fig. 2d). Usually, patients with rapid tumor growth and symptomatic visceral metastases were firstly treated with palliative chemotherapy, because these patients needed rapid control for the disease. Thus, Fulvestrant was used as second-line or even higher-line regimen for these patients. Undoubtedly, these patients had poor response for late-line Fulvestrant treatment. When PSM was used to evaluate prior palliative chemotherapy, none first-line users were included; all PSM patients for prior palliative
chemotherapy were second-line or higher-line patients; in this case, patients with prior palliative chemotherapy had no significant different PFS from patients with other prior palliative drug treatment.

According to current clinical researches, no report about the relationship between lymph node metastases and PFS prognosis has been demonstrated in Fulvestrant users. In our study, both COX regression analysis and PSM analysis showed a significant risk effect of lymph node metastases against PFS in Fulvestrant users (Fig. 2b). But, these results need to be carefully interpreted. More well-designed perspective studies are required to confirm our results.

As for visceral metastasis, it is another important clinical event for evaluation. FALCON trial has suggested that non-visceral metastasis patients benefit more from Fulvestrant [11]. However, Kawaguchi H reports that visceral metastasis is irrelevant to PFS in Fulvestrant users [12], which is similar to our findings. We suppose that distinct enrollment criterion lead to such a

---

**Table 3 ctDNA gene mutations of 16 Fulvestrant second- or higher-line users**

| Covariate   | Overall (N = 16) | PFS subgroups |
|-------------|------------------|---------------|
|             | PFS < 6 months (n = 10) | PFS > 6 months (n = 6) | p-value* |
| PIK3CA      | 10 (62.50%)       | 7 (70.00%)    | 3 (50.00%)  | 0.61  |
| TP53        | 4 (25.00%)        | 3 (30.00%)    | 1 (16.67%)  | 1.00  |
| ESR1        | 2 (12.50%)        | 2 (20.00%)    | 0 (0%)      | 0.50  |
| ERBB2       | 4 (25.00%)        | 4 (40.00%)    | 0 (0%)      | 0.23  |
| ESR1/ERBB2 | 6 (37.50%)        | 6 (60.00%)    | 0 (0%)      | 0.03  |
| TP53/ESR1/ERBB2 | 8 (50.00%) | 7 (70.00%)    | 1 (16.67%)  | 0.11  |

According to their PFS lengths, these patients were divided into two subgroups: PFS < 6 months and PFS > 6 months

* p-values were calculated by using Fisher’s exact tests (n < 5) for categorical variables comparison between PFS < 6 months group and PFS > 6 months group
discrepancy. The enrolled patients in FALCON trial are ER-positive/HER2-negative patients without any prior endocrine therapy. But in our retrospective study, most (73.53%) patients had received prior adjuvant endocrine therapy after surgery (Table 1). After long-term treatment, our patients more or less had intrinsic or required drug-resistance, so their treatment response to Fulvestrant would be inferior to the patients in FALCON trial. In addition, invisible visceral micro-metastasis might be another reason for such discrepancy. As we known, micro-metastasis sometimes exists even after mastectomy surgery and adjuvant chemotherapy [26, 27]; but current clinical tools cannot detect these micro-metastases, especially for visceral micro-metastases. Therefore, inadequate evaluation for disease status in ABC patients would lead to insufficient treatment and rapid tumor progression.

Till now, no research about ctDNA gene mutations has been reported in Fulvestrant users. Therefore, in this study, we recruited 16 volunteers to screen their ctDNA profile when disease progressed after Fulvestrant treatment. Although the sample size was relatively small, but we still obtain some important clues for the molecular basis about Fulvestrant resistance. All recruited 16 patients received second- or higher-line Fulvestrant treatment. By using ctDNA testing, PI3KCA was found to be the most common (62.5%) mutated gene in these 16 patients. PI3KCA mutated patients with ESR1 or ERBB2 mutation had the shortest PFS. As shown in Table 3, 60% patients in PFS<6 months group had ESR1 or ERBB2 mutation. Two ESR1 mutated patients (ID = 11 and ID = 12) were both ABC patients with prior aromatase inhibitors (AI) treatment. In ER-positive patients, ESR1 mutation is not only associated to AI treatment failure [28], but also induces drug resistance to Fulvestrant [19]. The cross-talk between PI3K and ER pathway and between PI3K/ERBB2 pathway also cause patients’ resistance to endocrine therapy [17]. In COX regression analysis, HER2-positive status was also confirmed as a risk factor for poor prognosis (Table 2 and Additional file 1: Table S1).

There were some limitations in this study. First, in this single-center retrospective study, the sample size was relatively small, and we lacked drug efficiency comparison of Fulvestrant with other endocrine drugs. Second, in this retrospective observational study, none first-line Fulvestrant user received ctDNA testing. So, we could not get information about the mutation situation in first-line users. In fact, only 16 Fulvestrant second- or higher-line users received ctDNA testing. It was good for us to detect the ctDNA profile in treatment failure patients, but no dynamic ctDNA surveillance during Fulvestrant treatment was obtained for us to find other potential resistance-related mutations. In further investigation, we will continue to focus on Fulvestrant first line users and conduct ctDNA testing.

In recent years, clinical researches have made great effort to realize individualized treatment by optimizing clinical settings and targeting specific biological features [29]. Currently, anti-breast cancer therapy has entered an era of precision medication [30]. A double-blinded phase III clinical trial PALOMA-3 investigate the efficiency of Palbociclib plus Fulvestrant vs Fulvestrant alone in HR+/HER2− post-menopause patients with prior endocrine therapy failure; compared to Fulvestrant alone group, Palbociclib plus Fulvestrant shows a better prognosis [31]. Another random double-blinded placebo-controlled phase II clinical trial (PrE0102) shows that mTOR inhibitor Everolimus could improve Fulvestrant treatment outcome in AI-resistant ER-positive metastatic breast cancer (MBC) patients [32]; compared to Everolimus alone, Fulvestrant plus Everolimus could significantly prolong median PFS from 5.1 to 10.3 months [HR (95% CI) = 0.61 (0.40, 0.92), p = 0.02]. In addition, MONALEESA-3 trial proves that Fulvestrant has good treatment efficiency in both single drug treatment and combined regimen [33–35]. In future, more large-scale perspective research plus ctDNA surveillance would provide more useful clinical and genetic information about Fulvestrant treatment. Breast cancer patients would have more survival opportunity by using Fulvestrant-based combined targeting therapy.

**Conclusion**

First-line Fulvestrant usage could guarantee a better prognosis than higher-line usage. Fulvestrant first-line users had a median PFS of 15.67 months, which was longer than the second-line users and third (or higher)-line users (mPFS = 7.47 and 5.43 months, respectively). COX regression analysis showed that lymph node metastasis and HER-2 positive were significant risk factors for poor PFS; high ER-positive was a significant protective factor. In addition, ESR1 or ERBB2 mutation was found to be related to poor PFS in higher-line Fulvestrant users.

**Additional files**

**Additional file 1: Table S1.** Multivariate COX regression analysis for the risk factors for progression (PFS) and time-to-failure (TTF) in Fulvestrant users.

**Additional file 2: Figure S1.** ctDNA gene mutation profiles in Fulvestrant users, stratified by Fulvestrant lines, second-line users (A), and third or higher-line users (B). Dark red represents the most common mutated genes and dark blue represents the rarest mutations. If the mutated genes appeared at the same frequency, they are ranked in alphabetic order.
Abbreviations
BC: breast cancer; HR: hormone receptor; ABC: advanced breast cancer;
mPFS: median progression-free survival; PFS: progression-free survival; ctDNA: circulating tumor DNA; HR: hazard ratio; ER: estrogen receptor; QOL: quality of life; SERD: selective ER degrader; TTP: time-to-progression; CI: confidence interval; OS: overall survival; ASCO: American Society of Clinical Oncology; DFS: disease free survival; HER2: human epidermal growth factor receptor 2; gDNA: genomic DNA; SNV: single nucleotide variants; Indels: insertions and deletions; PSM: propensity score matching; KM: Kaplan–Meier; ROC: receiver operating characteristic; TTF: time to treatment failure; MBC: metastatic breast cancer.

Authors' contributions
QO had full access to all data in the study and takes responsibility for the integrity and accuracy of the data analysis. Study concept and design: QO and ZH. Data acquisition: JL1, JL2 and QH. Data analysis and interpretation: ZH, JL1 and JL2. Drafting of the manuscript: JL1, JL2, ZH and YW. Critical revision of the manuscript for important intellectual content: JL1, ZH, JL2, HW, YW, QH, XX, and QQ. All authors read and approved the final manuscript.

Author details
1 The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University / Hunan Cancer Hospital, Changsha 410013, China. 2 Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital, No. 283, Tongzi Road, Changsha 410013, People’s Republic of China. 3 Key Laboratory of Translational Radiation Oncology of Hunan Province (2015STP1009), Changsha 410013, China. 4 Department of Biostatistics and Bioinformatics, Emory University Rollins School of Public Health, Atlanta 33022, USA. 5 Geneplus Beijing Institute, Beijing 102206, China.

Acknowledgements
We would like to thank the researchers from Geneplus Beijing Institute as these individuals sequenced all patients’ ctDNA and gDNA samples for this study.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
Not applicable.

Consent for publication
Informed consent was obtained from each patient prior to study onset.

Ethics approval and consent to participate
The study was approved by the Ethics Committee at the Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University.

Funding
This study was supported by Natural Science Foundation of Hunan Province (2018SK2124) and Hunan Provincial Health and Sanitation Committee Foundation (B2019085).

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 17 September 2018 Accepted: 6 December 2018
Published online: 15 January 2019

References
1. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomarkers Prev. 2016;25:16–27.
2. Park S, Han W, Kim J, Kim MK, Lee E, Yoo TK, Lee HB, Kang YJ, Kim YG, Moon HG, Noh DY. Risk factors associated with distant metastasis and survival outcomes in breast cancer patients with locoregional recurrence. J Breast Cancer. 2015;18:160–6.
3. Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, Andre F, Harbeck N, Lopez-Abad B, Barrios CH, Bergh J, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4) [Google Scholar]. Ann Oncol. 2018;29:1634–57.
4. Wakeling AE. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer. 2000;7:17–28.
5. Howell A, Robertson JF, Quaresma Albano J, Achermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002;20:3396–403.
6. Pritchard KI, Rolski J, Papaz L, Mauriac L, Cardoso F, Chang J, Panasci L, Januli C, Kahan Z, Fukase K, et al. Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). Breast Cancer Res Treat. 2010;123:453–61.
7. Ohno S, Rai Y, Iwata H, Yamamoto N, Yoshida M, Iwase H, Masuda N, Nakamura S, Taniguchi H, Kamigaki S, Noguchi S. Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). Ann Oncol. 2010;21:2342–7.
8. Kuter I, Gee JM, Hegg R, Singer CF, Badwe RA, Lowe ES, Emeribe UA, Anderson E, Sapunar F, Finlay P, et al. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study. Breast Cancer Res Treat. 2012;133:237–46.
9. Howell A, Pippin J, Elledge RM, Mauriac L, Vergote I, Jones SE, Come SE, Osborne CK, Robertson JF. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer. 2005;104:236–9.
10. Di Leo A, Jerusalem G, Petruzella L, Torres R, Bondarenko IN, Khasanov F, Verhoeven D, Pedrini JL, Smirnova I, Lichtenstet MR, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28:4594–600.
11. Robertson JFR, Bondarenko IM, Trishkina E, Dvorinik M, Panasci L, Manikanas A, Shparyk Y, Cardona-Huerta S, Cheung KL, Philo-Salas MJ, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase III trial. Lancet. 2016;388:2997–3005.
12. Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Tokunaga E, et al. Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari). Breast Cancer Res Treat. 2017;163:545–54.
13. Graham J, Pitz M, Gordon V, Grenier D, Amir E, Nirla R. Clinical predictors of benefit from fulvestrant in advanced breast cancer: a meta-analysis of randomized controlled trials. Cancer Treat Rev. 2016;45:1–6.
14. Koizumi K, Koga C, Akiyoshi S, Masuda T, Iijichi H, Nakamura Y, Ishida M, Ohno S, Tokunaga E. Impact of visceral metastasis on efficacy of fulvestrant in patients with hormone receptor-positive recurrent breast cancer. Anti-Cancer Res. 2018;38:1579–84.
15. Tsuibo K, Kaneko Y, Nagatomo T, Fujiyama T, Hanamura T, Gohono T, Yamaguchi Y, Niwa T, Hayashi SJ. Different epigenetic mechanisms of ERα/β implicated in the fate of fulvestrant-resistant breast cancer. J Steroid Biochem Mol Biol. 2017;167:115–25.
16. Bailey ST, Shin H, Westerling T, Liu XS, Brown M. Estrogen receptor prevents p53-dependent apoptosis in breast cancer. Proc Natl Acad Sci USA. 2012;109:18060–5.
17. Ribas R, Pancholi S, Rani A, Schuster E, Guest SK, Nikitovorowicz-Buniak J, Simigdala N, Thornhill A, Avogadri-Connors F, Cutler RE Jr, et al. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer. Breast Cancer Res. 2018;20:244.
18. Jeselsohn R, De Angelis C, Brown M, Schiff R. The evolving role of the estrogen receptor mutations in endocrine therapy-resistant breast cancer. Curr Oncol Rep. 2017;19:35.
19. Kuang Y, Siddiqui B, Hu J, John M, Cornwell M, Buchwalter G, Hughes ME, Wagle N, Kirschmeier P, Janne PA, et al. Unraveling the clinicopathological features driving the emergence of ESRT mutations in metastatic breast cancer. NPJ Breast Cancer. 2018;4:22.
20. Hu ZY, Xie N, Tian C, Yang X, Liu L, Li J, Xiao H, Wu H, Lu J, Gao J, et al. Identifying circulating tumor DNA mutation profiles in metastatic breast cancer patients with multiline resistance. EBioMedicine. 2018;32:111–8.
21. Board RE, Wardley AM, Dixon JM, Armstrong AC, Howell S, Renshaw L, Donald E, Greystoke A, Ransom M, Hughes A, Dive C. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res Treat. 2010;120:461–7.
22. Madic J, Kiialainen A, Bidard FC, Birzelle F, Ramey G, Leroy Q, Rio Frio T, Vaucher I, Raynal V, Bernard V, et al. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. Int J Cancer. 2015;136:2158–65.
23. Lalchandani UR, Sahai V, Hersberger K, Francis IR, Wasnik AP. A radiologist’s guide to response evaluation criteria in solid tumors. Curr Probl Diagn Radiol. 2018. https://doi.org/10.1067/j.cpradion.2018.07.016.
24. Saad ED, Katz A. Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined. Ann Oncol. 2009;20:460–4.
25. Li L, Pan Z. Progression-free survival and time to progression as real surrogate end points for overall survival in advanced breast cancer: a meta-analysis of 37 trials. Clin Breast Cancer. 2018;18:63–70.
26. Yousefi M, Nosrati R, Salmaninejad A, Dehghani S, Shahryari A, Saberi A. Organ-specific metastasis of breast cancer: molecular and cellular mechanisms underlying lung metastasis. Cell Oncol (Dordr). 2018;41:123–40.
27. Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M, Yan J, Hua Y, Tiede BJ, Haftty BG, et al. VCAM-1 promotes osteolytic expansion of indolent bone micro-metastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell. 2011;20:701–14.
28. Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. ESR1 mutations–a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015;12:573–83.
29. Sun J, Huang Z, Hu Z, Sun R. Benefits of local tumor excision and pharyngectomy on the survival of nasopharyngeal carcinoma patients: a retrospective observational study based on SEER database. J Transl Med. 2017;15:116.
30. Bettaieb A, Paul C, Pflcnette S, Shan J, Chouchane L, Ghiringhelli F. Precision medicine in breast cancer: reality or utopia? J Transl Med. 2017;15:139.
31. Cristofanilli M, Turner NC, Bondarenoo L, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425–39.
32. Kornblum N, Zhao F, Manola J, Klein P, Ramaswamy V, Brufsky A, Stella PJ, Burnette B, Telli M, Makower DF, et al. Randomized phase II trial of Fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PRe0102. J Clin Oncol. 2018;36:1556–63.
33. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentis M, Im SA, Petakova K, Bianchi GV, Esteva FJ, Martin M, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36:2465–72.
34. Kundig P, Giesen C, Jackson H, Bodenmiller B, Papassotiriopoulos B, Freiberger SN, Aquino C, Opitz L, Varga Z. Limited utility of tissue microarrays in detecting intra-tumoral heterogeneity in stem cell characteristics and tumor progression markers in breast cancer. J Transl Med. 2018;16:118.
35. Wang X, Yang Q, Guo L, Li XH, Zhao XH, Song LB, Lin HK. Flotillin-2 is associated with breast cancer progression and poor survival outcomes. J Transl Med. 2013;11:190.